Prof Frank Griesinger, medical oncologist at Pius Hospital, Oldenburg, Germany presents real-world data and outcomes in the US and Germany after first-line treatment with osimertinib in patients with EGFRm advanced NSCLC. With the educational support of: You may also be interested in: Real-world data after first-line osimertinib Real-world evidence of IO treatment in lung cancer: a Belgian multicenter study FLAURA2 post-progression outcomes Tags:poster